AUA Guidelines Expand Aquablation Therapy Recommendation for BPH Treatment

Event summary

  • AUA updated guidelines to strengthen recommendation for Aquablation therapy as a surgical treatment for BPH in prostates 30–80 mL, with expanded use for 80–150 mL prostates.
  • Guidelines reflect randomized clinical trial data showing durable improvements in urinary symptoms and flow rates through five years.
  • Update follows recent EAU guideline momentum, which also included a strong recommendation for Aquablation therapy.
  • PROCEPT BioRobotics' Aquablation therapy is supported by 250 peer-reviewed publications.

The big picture

The AUA guideline update underscores the growing clinical validation of Aquablation therapy, positioning it as a preferred surgical option for BPH. This aligns with broader industry trends toward minimally invasive, robotics-assisted urological procedures, particularly as the aging male population expands. PROCEPT BioRobotics' ability to leverage this momentum will depend on its execution in expanding market reach and securing reimbursement.

What we're watching

Adoption Dynamics
How the expanded AUA recommendation will accelerate Aquablation therapy adoption among urologists and hospitals.
Clinical Validation
Whether the durable outcomes demonstrated in clinical trials will translate into long-term market preference over competing BPH treatments.
Regulatory Momentum
The pace at which other global guidelines will follow AUA and EAU in strengthening recommendations for Aquablation therapy.

Related topics

Medical Devices